# Sintilimab Plus NCT or NCRT Versus NCRT for ESCC

> **NCT05244798** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Sichuan Cancer Hospital and Research Institute** · enrollment: 420 (estimated)

## Conditions studied

- Esophageal Squamous Cell Carcinoma

## Interventions

- **DRUG:** Sintilimab
- **RADIATION:** radiotherapy
- **DRUG:** Chemotherapy

## Key facts

- **NCT ID:** NCT05244798
- **Lead sponsor:** Sichuan Cancer Hospital and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2022-11-01
- **Primary completion:** 2025-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 420 (ESTIMATED)
- **Last updated:** 2022-10-25

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05244798

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05244798, "Sintilimab Plus NCT or NCRT Versus NCRT for ESCC". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05244798. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*